One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap.
doi : DOI: 10.1161/CIRCULATIONAHA.124.069695
Volume 151(3) pgs. 199-287,e24-e30 January 21, 2025
Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease.
In Which Patients Will Percutaneous Coronary Intervention Relieve Angina?.
Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality.
Association Between Delay to First Shock and Successful First-Shock Ventricular Fibrillation Termination in Patients With Witnessed Out-of-Hospital Cardiac Arrest.
A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease.
Driving Restrictions and Incapacitation Vulnerability Evaluation After ST-Segment-Elevation Myocardial Infarction: DRIVE-STEMI Study.
ADMET-AI Enables Interpretable Predictions of Drug-Induced Cardiotoxicity.
An Advocacy Agenda for the Human Brain: Moving From Brain Health to Brain Capital.
Letter by Wang and Peng Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".
Response by Park and Kang to Letter Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".
Correction to: Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial.
Correction to: Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.
